TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04792034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine Hydrochloride Topical Solution
Description: Topical Anesthetic
Study: NCT05361538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True circular microwave needle
Description: Use true circular microwave needle for thermal ablation
Study: NCT04981847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention Meetings
Description: Participants will attend classes once per week for 3 months.
Study: NCT05828615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9).
Study: NCT05317650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-gravitational suspension-based therapy (M-Gravity)
Description: Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
Study: NCT05712265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: Miricorilant 6 x 100 mg coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine 50 mg tablet
Study: NCT05101733

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal provocation
Description: Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin-Prick Test
Description: Skin-Prick-Test is administered to determine an allergy against Alternaria

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: For further analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: For further analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of nasal secretion
Description: Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of nasal secretion
Description: Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
Study: NCT05833230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Day Monitoring
Description: During intake, a research assistant will demonstrate how to place the Heart Rate Variability monitor and provide instructions on completing the saliva samples at home. Participants will wear the Heart Rate Variability monitor for three consecutive, randomly selected days twice (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. All participants will complete a total of 6 such days during the study.
Study: NCT05169736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
Study: NCT04836507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRC01
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study: NCT04917367

Intervention type: PROCEDURE
Intervention: exploratory surgery
Description: For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies.

Intervention type: PROCEDURE
Intervention: exploratory surgery
Description: For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies.
Study: NCT04839393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 followed by PF-06882961/PF-06865571
Description: Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961/PF-06865571 followed by PF-06882961
Description: Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 + PF-06865571
Description: Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
Study: NCT06020833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat in combination with retinoic acid
Description: Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
Study: NCT06262191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Differential and adjustable stiffness AFO (DAS-AFO)
Description: Walking with a differential and adjustable stiffness AFO (DAS-AFO)
Study: NCT04021485

Intervention type: OTHER
Group type: OTHER
Intervention: neurodevelopmental assessment
Description: As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire
Study: NCT06287541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine biomarker -Guided without reTURBT
Description: Participants will proceed without reTURBT
Study: NCT06075134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botox injection
Description: Botox injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox injection
Description: Botox injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG
Description: Quantitative Electromyography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplement
Description: To increase efficacy of Botox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: To increase efficacy of Botox
Study: NCT05791513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice
Description: The consultation between clinician and adolescent is conducted as per usual practice.
Study: NCT04898127

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antigen rapid test
Description: Rapid test before access to mass gathering event (concert), provided the test result is negative.
Study: NCT06423872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT002
Description: Participants will receive a single subcutaneous (SC) ZT002 injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive same volume as of the study drug.
Study: NCT05344430

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Description: We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Description: We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
Study: NCT05660889

Intervention type: OTHER
Intervention: Blood sampling.
Description: Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.

Intervention type: OTHER
Intervention: Blood sampling.
Description: Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
Study: NCT05908981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sandalwood aromatherapy (Santalum album)
Description: Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sandalwood aromatherapy (Santalum album)
Description: Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
Study: NCT05446922

Intervention type: OTHER
Group type: OTHER
Intervention: Diffusion MRI
Description: All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
Study: NCT06349850

Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid level to plasma HDL-c level ratio (UHR)
Description: high UHR is considered to be a risk factor for development of DKI in type 2 DM

Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid level to plasma HDL-c level ratio (UHR)
Description: high UHR is considered to be a risk factor for development of DKI in type 2 DM

Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid level to plasma HDL-c level ratio (UHR)
Description: high UHR is considered to be a risk factor for development of DKI in type 2 DM
Study: NCT05833009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
Study: NCT06031987

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CareSens N (iSENS)
Description: Control group is asked to perform SMBG (4 times or more per day).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre (Abbott)
Description: CGM group is asked to scan CGM (4 times or more per day).
Study: NCT05836116

Intervention type: OTHER
Intervention: Evaluation of Muscle Activation
Description: Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application.

Intervention type: OTHER
Intervention: Evaluation of Muscle Activation
Description: Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application.
Study: NCT04995627

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt (NaCl)
Description: 12 grams of salt (NaCl) per day
Study: NCT05511506

Intervention type: OTHER
Group type: OTHER
Intervention: aqueous humor collection
Description: Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.

Intervention type: OTHER
Group type: OTHER
Intervention: aqueous humor collection
Description: Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
Study: NCT04631952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise
Description: SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message
Description: SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
Study: NCT04995627

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04892472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200T
Description: All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475) 200 mg
Description: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475) 200 mg
Description: Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
Study: NCT06483321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
Study: NCT05001932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Randomized Clinical Trial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Randomized Clinical Trial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Randomized Clinical Trial

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Randomized Clinical Trial
Study: NCT05352347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.2 mg/kg
Description: NuSepin® 0.2 mg/kg in 100mL NS bid
Study: NCT06046092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7HLAII
Description: DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
Study: NCT06502522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes.
Study: NCT06424821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab + chemotherapy
Study: NCT05860907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: 10g each time, three times a day
Study: NCT05937386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDZ
Description: Pre-filled oral syringes
Study: NCT05802420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Later-line therapy
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy